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Outcomes of Patients Referred for Arteriovenous Fistula 
Construction: A Systematic Review 
Andrew Stanton Kucey,1 Anish Engineer,2 Shawn Stefan Albers.1 
Abstract 
Chronic Kidney Disease (CKD) affects 10-16% of the US population and its incidence is rising due to increasing prevalence of associated risk factors. Renal 
replacement therapy is required to treat late stage CKD and hemodialysis is the preferred modality for many patients. Vascular access is required for 
hemodialysis and arteriovenous fistulas (AVF) are currently the gold standard. This review intended to collate current knowledge on AVF outcomes regarding 
both the patient and fistula. Scopus and Medline were utilized to identify relevant literature. Inclusion and exclusion criteria were applied to narrow search 
results. Among CKD patients, 33.5-77.4% require a central venous catheter (CVC) before dialysis through a fistula. Many patients (33-51%) use a CVC 
regardless of AVF creation due to fistula immaturity or failure. There are large variations in AVF creation policies internationally; 16% of American 
hemodialysis patients use a fistula compared to 72% of German patients. Primary patency and primary AVFs' failure ranges from 60-70% and 20-26%, 
respectively. AVFs reduce morbidity and mortality in CKD. At present, too many patients are receiving hemodialysis through a CVC. Inadequate referral 
times for AVF creation can lead to fistula immaturity or failure in the intervention. Many countries are lagging behind recommended AVF creation rates 
published by the Kidney Disease Outcomes Quality Initiative. There is a paucity of literature concerning when a patient should be referred for AVF creation. 
It is paramount to have better predictive outcome measures and more clarity as to when patients will benefit from an AVF. 
 
Key Words: Arteriovenous Fistula; Vascular Access Devices; Hemodialysis; Vascular Surgical Procedures; Chronic Renal Insufficiency (Source: MeSH-NLM). 
 
 
Introduction 
Chronic Kidney Disease (CKD) is a pathologic condition resulting in a 
progressive decline of kidney function. It currently affects 7-12% of 
individuals globally, while its incidence is rapidly rising.1-4 The disease 
involves structural pathology such as nephron loss and fibrosis, which 
result in decreased glomerular filtration.5 These insults to the kidney 
contribute to systemic complications of CKD, including fluid and 
electrolyte abnormalities, anaemia, mineral-bone disorder, metabolic 
acidosis, hyperuricaemia, hypertension, dyslipidemia, cardiovascular 
disease and endocrine dysfunction.5 Severity of the disease can be 
divided into five stages depending on estimated glomerular filtration 
rate (eGFR), with substantial loss of kidney function and end-stage 
renal disease (ESRD) comprising stages IV and V, respectively.6-8 Renal 
replacement therapy is necessary once a patient has progressed to 
ESRD. Kidney transplants are ideal for renal replacement; however, they 
are not widely accessible. Consequently, hemodialysis (HD) is often the 
modality of choice for patients in ESRD.9  
 
The process of HD clears the blood of uremic toxins using a series of 
pumps, membranes and dialysates. Patients undergoing this long-term 
therapy require permanent vascular access placement, as suggested by 
the Kidney Disease Outcomes Quality Initiative (KDOQI).1,8,10 The three 
main types of vascular access include arteriovenous fistulae (AVF), 
arteriovenous grafts (AVG) and central venous catheters (CVC).8 The 
current gold-standard for HD access is the formation of an AVF, as it is 
clinically reported to have better patient outcomes with reduced 
morbidity and improved survival.8,10-13 AVFs are established in the 
forearm through surgical anastomosis of a relatively small, peripheral 
artery with a larger subcutaneous vein.14 According to the KDOQI, the 
optimal timing for AVF creation is 6 months before cannulation, 
however this maturation can be affected by factors, such as age and 
gender.8,11  In the case where a patient’s vascular integrity does not 
support a fistula, an AVG can be implemented. Studies indicate that 
AVGs have more drawbacks compared to AVFs. These include higher 
infection susceptibility potentially resulting in sepsis, reduced patency, 
and greater risk of complications ultimately leading to repeated 
interventions and diminished survival.15 CVCs, on the other hand, are 
generally employed prior to AVF or AVG maturation, when immediate 
initiation of HD is required. Infection and thrombosis among other life 
threatening complications, are persisting impediments.16 For instance, 
Lee et al. noted that catheter-related bacteremia was present in half of 
all HD patients studied 6 months after CVC implantation.17 Furthermore, 
HD patients with CVCs have a 3.43-fold increase in relative mortality 
risk compared to patients with an AVF.17-19 
 
Therefore, AVFs are the gold standard method to attain vascular access 
in patients undergoing HD, as they result in fewer complications when 
compared to CVCs and AVGs.8,10-13 However, to better maintain access 
sites and retain the integrity of the vasculature, radiocephalic AVFs 
(RCAVF) are the recommended option by the KDOQI, and are associated 
with improved patient survival.12,20 In cases where the creation of a 
RCAVF is not feasible due to poor vasculature brachiocephalic, 
brachiobasilic, and brachiobrachial AVFs can be created.21 In spite of 
the clear benefits provided by AVFs for HD patients, they do carry some 
drawbacks and can potentially pose a risk for serious complications 
requiring hospitalization.22 The reported complications surrounding 
fistulas include aneurysm development, stenosis of the vein, dialysis-
associated steal syndrome (due to ischemia), thrombosis, and 
infection.22 Additionally, the primary failure rates of AVF formation and 
maturation are approximated at 23% and 20-60%, respectively.1,23-25 
Indeed, AVFs are a source of patient morbidity, however, they still 
remain the principal type of vascular access for HD compared to AVGs 
or CVCs.8,21 To ensure its success, the timing of AVF creation relative to 
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HD must be considered. As there exists a long lag time between AVF 
formation and usage, fistulas can be created in a pre-emptive manner 
to circumvent potential CVC access, if HD is required. Even so, if the 
AVF is not needed or not used for access by the patient, the surgical 
procedure to create the fistula can result in unwarranted patient 
distress.1 Moreover, the average maturation time for an AVF falls 
between 148 to 285 days, with a 75% successful cannulation rate at 16 
weeks (112 days) post-surgery.1,25,26  
 
Taking the aforementioned factors into account, the temporally 
sensitive nature of this complex therapeutic intervention must be 
considered at the time of consultation. The time-course for formation 
of the fistula needs to be appropriately managed from initial patient 
referral to when the mature AVF will be needed. As the incidence of 
CKD rises, more patients will require renal replacement therapy and the 
creation of an AVF for HD. Therefore, it is imperative that we analyze 
and examine current practices to determine the best course of action. 
 
Objectives 
This review will analyze the literature on arteriovenous fistulas used for 
vascular access to determine the current paradigms on: 
 
1) Outcomes regarding the patient after AVF creation 
i. The proportion of patients who end up on dialysis 
ii. The number of patients who require a central line due to 
AVF immaturity or failure 
iii. Whether the patient receives a transplant and avoids 
dialysis or dies before dialysis commencement 
iv. Estimated prognosis between AVF and non-AVF patients 
2) Outcomes regarding the fistula itself 
i. Primary AVF patency, secondary AVF patency 
ii. Primary and secondary AVF failure 
iii. Fistula maturation times 
3) Predictive factors for AVF outcomes 
i. Sex, morbidity, lifestyle, site of fistula 
ii. Vein diameter, arterial flow rate. 
 
Methods 
Search Strategy 
An electronic search was conducted using the databases of Medline 
(PubMed) and Scopus. The search identified publications pertaining to 
the objectives and research question of the current study. 
 
Medline (PubMed): 
("arteriovenous fistula"[MeSH Terms]) OR ("arteriovenous"[All Fields] 
AND "fistula"[All Fields]) OR ("arteriovenous fistula"[All Fields] AND 
“creation”[All Fields] AND "blood vessels"[MeSH Terms]) OR ("blood"[All 
Fields] AND "vessels"[All Fields]) OR ("blood vessels"[All Fields]) OR 
("vascular"[All Fields]) AND “access”[All Fields] AND “outcomes”[All Fields]) 
 
This search returned 171 results. The results were narrowed down to 
61 publications after filtering for free, full-text, and again to 49 results 
after specifying for human studies. The inclusion and exclusion criteria 
were applied to the abstracts of the remaining 49 papers. This narrowed 
the search to 6 papers. The abstracts were screened by all three authors 
and conflicts regarding inclusion and exclusion were resolved through 
group meetings. 
 
Scopus: 
(arteriovenous AND fistula AND creation AND for AND vascular AND 
access AND outcomes) 
 
This search returned 383 results. After filtering for open access 
publications, 65 papers remained. Filtering for human studies, English 
availability, articles, and reviews narrowed the results to 58. The 
remaining articles had their abstract subject to the inclusion and 
exclusion criteria. Nine publications were identified based on this, 5 of 
the papers overlapped with the Medline results. 
 
In total, 10 articles were identified between the two database searches 
(Figure 1). 
 
Study Eligibility: 
The inclusion and exclusion criteria were generated a priori. Studies 
were included if they addressed populations who underwent AVF 
creation for HD access, if primary patency or AVF maturation were 
mentioned in the abstract and if the authors reviewed the outcomes of 
their subjects after AVF creation. The selected manuscripts all present 
new data published in its first report and are not review papers. 
 
Exclusion criteria specified studies carried out on non-human species, 
articles not available in English, and articles that were not available as 
Open Access. Additionally, papers addressing exclusively elderly or 
adolescent populations were removed. Finally, articles were excluded 
if the study evaluated endovascular fistula creation, focused primarily 
on anaesthetic technique or on steal syndrome, or if the study 
addressed AVF interventions and revisions rather than primary creation, 
it was excluded.  
 
Definitions: 
 Primary Patency – Time from AVF creation until thrombosis or 
until an intervention was required to maintain flow 
 Secondary (cumulative) Patency – Time from AVF creation until 
abandonment  
 Primary Assisted 1-year Patency – Measures whether the AVF was 
able to survive 1 year after cannulation with or without 
interventions 
 Time to Maturation – Time from fistula creation until it is 
successfully cannulated  
 Primary Failure – AVF was never suitable for dialysis cannulation 
 Functional Primary Patency – Time from fistula cannulation until 
AVF failure or until the first intervention is required. 
 
Figure 1. Flow diagram of study methodology with application of 
inclusion and exclusion criteria 
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Results 
All of the papers identified by the search methods were assessed for 
their quality and validity using the Evidence-based librarianship (EBL) 
critical appraisal tool.27,28 The abbreviated results are displayed in Table 
1 and the extended appraisal can be viewed in Appendix A. All of the 
selected articles were deemed valid when applying the EBL criteria. 27 
The methodology of all the papers identified to be eligible for review 
were adequate and minimized bias that the individual study may be 
susceptible to. 
 
Patient Outcomes 
A retrospective study looking at HD patients in Canada showed that 
27% patients had at least one AV access created in a study population 
of 17,183 (Table 2).29 Of the patients who had an AVF created, 65% were 
able to cannulate it for HD, while 33% had to resort to a CVC.29 Of the 
patients who were referred late to a nephrologist, 8% had an AV access 
created as opposed to 39% who were referred early.29 Prior to AVF 
creation, CVC use occurred in 35.7-77.4% of patients.13,21,26,30,31  A study 
investigating the natural history of AVFs noted that 66% of vascular 
access procedures were to create an AVF, with 33% of these being 
RCAVFs.26 Four studies reported that 48-75% of AVFs were being used 
for HD at the time of follow-up, while 37-51% of them were 
abandoned.1,25,26,30,32 A study on pre-emptive AVF creation showed 49% 
of patients ended up on HD during their 10 month follow-up with 65% 
of these patients being dialyzed through their AVF.1 This paper also 
reported that 23% of the patients never used their viable AVF for HD.1  
 
A paper which assessed vascular access use since the dialysis 
outcomes and practice patterns study, found that 27% of Canadian 
and16% American HD patients were being dialyzed through an AVF.13 
This is in contrast to 72% of German and 69% of Japanese HD patients 
who utilized an AVF.13 The proportion of HD patients using an AVG was 
highest in America at 15%, followed by Sweden at 9%.13 
 
Table 1. Results of the EBL Critical Appraisal of selected articles for review. 
 
Article 
Population 
Validity 
Score (%) 
Data 
Collection 
Validity 
Score (%) 
Design 
Validity 
Score 
(%) 
Results 
Validity 
Score 
(%) 
Overall 
Score 
(%) 
Al-Jaishi et al 
(2015)29 100 80 100 100 95 
Biuckians et 
al (2008)26 75 80 100 100 90 
Dageforde et 
al (2015)30 75 80 100 100 90 
Ethier et al 
(2008)13 66 80 100 100 86 
Kimball et al 
(2011)1 75 80 100 100 90 
Korepta et al 
(2016)21 66 80 100 100 86 
Lee et al 
(2012)33 66 80 100 100 86 
Masengu et 
al (2016)32 75 80 100 100 90 
Schinstock 
et al (2001)31 100 80 100 100 95 
Wilmink et al 
(2016)25 100 80 100 100 95 
 
AVF Outcomes 
Four studies reported an average AVF maturation time of 148-285 days with 
a cumulative functional 1-year patency of 60-70%.1,21,26,32 Primary failure was 
recorded in 3 studies and occurred in 20-26% of cases.25,26,31 In one study, 
AVFs failed to mature 20% of the time.30 Primary assisted 1-year patency 
was only measured in one study, and it was found to be 93-100%.21 
Complications occurred in 21.2% of AVFs and 54% of interventions occurred 
before maturation was achieved.31 RCAVF were shown to have a higher 
primary failure rate but better overall survival than brachiocephalic and 
brachiobasilic fistulas.25 When the AVFs were allowed to mature for 10 and 
16 weeks, they had a 50% and 75% survival respectively upon cannulation.25 
 
Pre-Operative Vasculature Status & AVF Outcomes 
Dageforde et al. showed that minimum vein diameter is associated with 
lower risk for AVF failure.30 Veins < 2.7 mm in diameter had > 33% failure 
to mature at 6 months.30 A patent upper arm cephalic vein was shown 
to improve primary patency, secondary patency and maturation in 
patients undergoing RCAVF creation.33 RCAVFs with arterial flow rates < 
50 mL/min were shown to have a 7 fold increase in failure rate.32 The 
flow rate was also shown to be a more sensitive marker than vein 
diameter when assessing failure to mature.32 
 
Multivariate Analysis on AVF Outcome Predictors 
Cox regression analysis associated female gender, being on dialysis at 
the time of AVF creation, and diabetes with worse AVF survival.25 
Dageforde et al. also showed that preoperative dialysis was associated 
with higher risk of AVF failure.30 The study by Wilmink et al. also 
demonstrated that females were associated with higher primary failure 
and longer maturation times.25 One study found that an age  65 years 
was an independent predictor of secondary AVF patency.33 Those less 
likely to have an AVF created were females, as well as patients with a 
high number of comorbidities.29 Gender was shown to be unassociated 
with primary or secondary patency by Schinstock et al., however, body 
mass index (BMI), diabetes, AVF site, previous CVC use, and the 
diameter of the artery, were all associated with primary patency.31 
While diabetes did not have an association with secondary patency, 
increased age and thromboembolic disease status were related to 
secondary patency in addition to the aforementioned factors.31 Kimball 
et al. found no relation between sex, BMI, smoking, age, race, fistula 
location and rate of AVF abandonment.1 Another study failed to identify 
individual predictors of AVF failure from factors including smoking, age, 
sex, BMI, diabetes, hypertension and hyperlipidemia.21 Finally, in a study 
looking at minimum vein diameter for AVF outcome prediction, coronary 
artery disease was associated with a lower risk of AVF failure overall.30 
 
Discussion 
This systematic review intends to combine recent investigations on 
outcomes of patients who are referred for AVF creation. The outcomes 
were subdivided into those that pertained to patient prognosis and 
those that measured the success of the AVF itself. The findings of this 
review suggest that patients are not being referred at an adequate time 
for AVF creation based on current KDOQI guidelines as 33.5-77.4% of 
patients are requiring a CVC use before they are using their AVF for HD.8 
Even once an AVF was made, 33-51% of the patients still ended up on 
a CVC for HD due to AVF immaturity or failure.1,25,26,29,30,32 
 
There were vast differences between countries in regards to the uptake 
of the KDOQI recommendations for AVF implementation. These guidelines 
suggest that 65% of HD patients should be using a fistula for their HD 
sessions.8,29 Only 27% and 16% of HD patients from Canada and USA, 
respectively, were being dialyzed through an AVF.13 In contrast, 72% of 
German and 69% of Japanese HD patients were using an AVF.13 These 
stark contrasts between nations may reflect local policies regarding 
healthcare or surgical preference, as 15% of American HD patients were 
using AVGs, while the next highest country was Sweden with 9%.13 The 
level of access to vascular surgeons may also impact results across 
regions. This is especially applicable to the Canadian and American 
healthcare systems which have some of the longest wait times between 
AVF consultation and AVF creation.13,34 Encouragingly, the use of AVFs 
is on the rise in most countries while the use of AVGs is on the decline13 
Between 1996 and 2007, the largest changes occurred in the US where 
the use of AVFs jumped from 24% to 47%, while AVG usage dropped 
from 58% to 29% in HD patients.13 Despite the numerous drawbacks of 
an AVF procedure, it is still the best option of the available AV access 
modalities, and the literature supports its utility in terms of patient 
prognosis over AVGs and CVC.8,35 
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Table 2. Summary of reviewed publications, arranged alphabetically. 
 
Authors and 
Location Title Objectives 
Study 
Design 
Sample 
Size Population Key Findings 
Ahmed A. Al-
Jaishi, 
Charmaine E. 
Lok, Amit X. 
Garg, Joyce C. 
Zhang, Louise 
M. Moist 
(2015). 
London, 
Canada.29  
Vascular 
access 
creation 
before 
hemodialysis 
initiation and 
use: a 
population-
based cohort 
study 
To assess how 
many patients 
had AV access 
before HD 
 
To elucidate 
secular trends in 
AV access  
 
To estimate the 
effect of referral 
time on AV access 
creation 
Retrospe
ctive 
populatio
n-based 
cohort 
study 
 
n = 
17,183 
 
The study 
population 
consisted of 
adults who 
used HD as 
their first 
modality for 
renal 
replacement 
therapy 
between 
January 1, 2001 
and December 
31, 2010 
27% of patients had at least one AV access created with a 
median time of 184 days between the procedure and HD 
commencement 
 
65% of patients with an AV access were able to use it for 
dialysis, while 33% still had to use a CVC 
 
From 2001-2010 there was a decline in AV access creation 
before HD commencement; 32% to 22% (P < 0.001) 
 
8% of patients with a late referral to nephrology had an AVG or 
AVF created, compared to 39% with an early referral  
 
Andre 
Biuckians, 
Eric C. Scott, 
George H. 
Meier, Jean 
M. Panneton, 
Marc H. 
Glickman 
(2008). 
Norfolk, 
USA.26 
The natural 
history of 
autologous 
fistulas as 
first-time 
dialysis 
access in the 
KDOQI era 
To determine the 
natural history of 
AVFs in first time 
vascular access 
patients 
Retrospe
ctive 
chart 
review 
 
n = 80 
 
The study 
population 
consisted of all 
patients 
undergoing 
their first AVF 
creation from 
January 1, 2005 
until June 30, 
2005 in a single 
vascular 
practice 
75% of AV access candidates had prior CVC HD use 
 
67% of first-time access patients had an AVF created, 33% had 
an AVG 
 
33% received an RCAVF, 67% had a BCAVF. Time to first 
cannulation was significantly shorter in BCAVF than RCAVF 
(P=0.03) 
 
48% of AVF were being used for HD at follow up (mean time of 
278 days), and 11% matured without intervention 
 
Average maturation time was 148 days, cumulative functional 
patency at 1 year was 63% 
 
48% of AVFs were being used for HD 
 
37% of the AVFs were abandoned, 20% being from primary 
failure  
 
Leigh Anne 
Dageforde, 
Kelly A. 
Harms, Irene 
D. Feurer, 
David Shaffer 
(2015). 
Nashville, 
USA.30   
Increased 
minimum 
vein diameter 
on 
preoperative 
mapping with 
duplex 
ultrasound is 
associated 
with 
arteriovenous 
fistula 
maturation 
and 
secondary 
patency 
To determine 
whether vein 
diameter 
measured by 
preoperative 
duplex ultrasound 
is associated with 
fistula maturation 
and secondary 
patency  
Retrospe
ctive 
chart 
review 
 
n = 158 
 
The study 
population 
consisted of 
patients who 
had an AVF 
created from 
February 2009 
until June 2011 
Larger minimum vein diameter was associated with lower risk 
for AVF failure 
 
Greater than 33% of veins <  2.7mm failed to mature at 6 
months 
 
Multivariate analysis showed that for every 1mm increase in 
minimum vein diameter, the risk of failure to mature was 
reduced by 45% and there was a 36% reduction in risk of fistula 
failure (HR, 0.555; P=0.005 & HR, 0.639; P=0.001 respectively) 
 
20% of fistulas failed to mature 
 
53% of fistulas were used for HD within the study period 
 
49% of patients had prior tunnelled catheter use for HD  
 
Jean Ethier, 
David C. 
Mendelssohn, 
Stacey J. 
Elder, Takeshi 
Hasegawa, 
Tadao 
Akizawa, 
Takashi 
Akiba, 
Bernard J. 
Canaud, 
Ronald L. 
Pisoni (2008). 
Ann Arbor, 
USA.13 
Vascular 
access use 
and 
outcomes: an 
international 
perspective 
from the 
dialysis 
outcomes and 
practice 
patterns 
study  
To describe 
changes in 
vascular access 
trends since the 
dialysis outcomes 
and practice 
patterns study 
(DOPPS) 
Retrospe
ctive 
review of 
a 
prospecti
ve 
database 
 
 
DOPPS 
I n = 
16402 
 
DOPPS 
II n = 
12839 
 
DOPPS 
III n = 
7921 
 
n = 
37,162 
 
The study 
population was 
HD patients at 
participating 
centres from: 
France, 
Germany, Italy, 
Japan, Spain, 
the USA and the 
UK in DOPPS I. 
Centres in 
Australia, 
Belgium, 
Canada, 
Sweden and 
New Zealand 
were added for 
DOPPS II and III.  
 
In the interval between DOPPS I and DOPPS III, the use of AVFs 
in the USA increased from 24% to 47%. AVF use also increased 
in the UK, Australia, and New Zealand 
 
Spain, Italy and Germany saw their AVF use decline 
 
AVG use declined in all countries, the largest fall was 58% to 
29% in the USA 
 
CVC use increased in Europe, Canada and the USA from DOPPS 
I to III; 50% of patients from DOPPS II initiated HD with a CVC 
 
35.7% of patients used a CVC if they had seen a nephrologist 
 4 months prior to HD start, as opposed to 77.4% who were 
seen < 1 month prior to HD 
 
Patients with longer wait times for surgical referral and 
evaluation had  
lower odds of initiating HD with an AVF (AOR 0.89 per 5 days 
longer; P<0.0001) 
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Authors and 
Location Title Objectives 
Study 
Design 
Sample 
Size Population Key Findings 
Traci A. 
Kimball, Ken 
Barz, Kelly R. 
Dimond, 
James M. 
Edwards, and 
Mark R. 
Nehler (2011). 
Denver, 
Colorado and 
Portland, 
Oregon, USA.1 
Efficiency of 
the kidney 
disease 
outcomes 
quality 
initiative 
guidelines for 
preemptive 
vascular 
access in an 
academic 
setting 
To determine the 
efficiency of 
prophylactic AVF 
for HD 
 
To determine the 
incidence of HD 
within late stage 
CKD patients 
 
To determine AVF 
functional 
patency and 
morbidity within 
study population 
 
Retrospe
ctive 
chart 
review 
 
n = 150  
 
The study 
population was 
comprised of 
late stage CKD 
patients who 
underwent pre-
emptive AVF 
creation across 
2 academic 
centers. 
Median time from surgical consultation to AVF creation was 31 
days (min, max; 1, 400) 
 
At 10-month follow-up, 49% of patients were on HD and 65% of 
them were using their AVF 
 
35% of patients on HD who were not using their AVF did not 
have AVF failure 
 
23% never initiated HD but had a viable AVF, 28% never went 
on HD and also abandoned their AVF 
 
Mean maturation time for AVFs being used for HD was 285 days 
 
Incidence of AVF abandonment was 51% 
 
Lindsey M. 
Korepta, 
Jennifer J. 
Watson, Erin 
A. Elder, Alan 
T. Davis, M. 
Ashraf 
Mansour, 
Christopher 
M. Chambers, 
Robert F. Cuff, 
Peter Y. Wong 
(2016). Grand 
Rapids, USA.21 
Outcomes for 
forearm and 
upper arm 
arteriovenous 
fistula 
creation with 
the 
transposition 
technique 
To examine the 
rates of 
complication, 
failure, 
maturation, and 
patency in 
forearm cephalic 
vein (FACVT), 
upperarm 
cephalic vein 
(UACVT), and 
upper arm basilic 
vein 
transpositions 
(UABVT) for AVF 
creation  
 
Retrospe
ctive 
chart 
review 
 
n = 165 
 
All patients 
undergoing AVF 
creation via 
FACVT, UACVT, 
or UABVT from 
January 1, 2006 
until December 
31, 2012. 
57% of patients were using a tunneled CVC for HD before AVF 
creation 
 
Average vein diameter was 3.2mm to 3.9mm 
 
No significant differences between groups in terms of time to 
maturation, primary 1-year patency (63-70%), or primary 
assisted 1-year patency (93-100%) 
 
84% of FACVT, 88% of UACVT, and 86% of UABVT patients were 
able to use their AVF  
 
Average time to cannulation from when the AVF was created 
was 9.94.7 weeks 
J.H. Lee, J.H. 
Won, C.K. Oh, 
H.A. Jung 
(2012). 
Suwon, 
Republic of 
Korea.33  
Clinical 
significance 
of upper-arm 
cephalic vein 
patency in 
autogenous 
radio-cephalic 
wrist fistulas 
for 
hemodialysis 
To determine the 
role of upper-arm 
cephalic veins in 
RCAVF clinical 
outcomes 
Retrospe
ctive 
chart 
review 
 
 
n = 183 
 
The study 
population 
included 
consecutive 
patients having 
an RCAVF 
created from 
March 2003-
February 2009. 
 
Patients were 
divided into 
two groups 
depending on 
their upper-arm 
cephalic vein; 
stenosed or 
occluded were 
group B, group 
A had a patent 
lumen. 
 
Multivariate analysis showed upper arm cephalic vein status 
to be a predictor of primary and secondary patency in RCAVFs 
(P<0.005) 
 
Maturation failure within 8 weeks was significantly higher in 
group B (26.7% vs. 9.8% in group A; P<0.009) 
 
Group A had significantly longer mean primary patency 
(P=0.011), however secondary patency was not significantly 
different between groups A and B 
 
Overall primary patency and secondary patency were both 
significantly greater in group A than B (P<0.0001) 
Agnes 
Masengu, 
James 
McDaid, 
Alexander P. 
Maxwell, 
Jennifer B. 
Hanko (2016). 
Belfast, UK.32 
Preoperative 
radial artery 
volume flow 
is predictive 
of 
arteriovenous 
fistula 
outcomes 
To determine 
whether pre-
operative 
ultrasound 
analysis of 
vessels can 
predict AVF 
outcomes 
Retrospe
ctive 
cohort 
study 
 
n = 152 
 
The study 
population 
consisted of all 
patients from a 
single center 
who underwent 
AVF creation 
after 
ultrasound 
mapping of 
their blood 
vessels (from 
August 2011-
December 
2014). 
RCAVFs with arterial flow less than 50ml/min failed to mature 
7 times more often than those with higher flow rates (P<0.001) 
 
Radial artery volume flow < 50ml/min is a more sensitive 
measure for fistula failure to mature than mean vessel 
diameter of < 2.7mm 
 
69% of the AVFs were functionally patent, 60% of the AVFs 
achieved primary patency 
 
45% of AVFs failed to mature and were abandoned 
 
Females were associated with higher AVF failure to mature 
 
Carrie A. 
Schinstock, 
Robert C. 
Albright, Amy 
W. Williams, 
John J. Dillon, 
Eric J. 
Bergstralh, 
Outcomes of 
arteriovenous 
fistula 
creation after 
the fistula 
first initiative  
To determine the 
outcomes of AVFs 
created at a single 
clinic and factors 
that predict their 
patency 
Retrospe
ctive 
cohort 
study  
 
n = 293 
 
The study 
population was 
comprised of 
patients over 
18 years old 
who were 
undergoing 
their first AVF 
50.5% of AVFs were created after HD commencement  
 
Kaplan-Meir survival at 3, 6, 12, and 18 months for primary 
patency was 67%, 50%, 41%, and 30%; secondary patency was 
92%, 86%, 77%, and 73% respectively 
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Authors and 
Location Title Objectives 
Study 
Design 
Sample 
Size Population Key Findings 
Bernice M. 
Jenson, James 
T. McCarthy, 
Karl A. Nath 
(2011). 
Rochester, 
USA.31 
creation the 
Mayo Clinic. 
Univariate analysis showed arterial diameter predicts the 
primary and secondary AVF patency (HR, 0.83; 95% CI, 0.73 to 
0.94 and HR, 0.67; 95% CI,  0.55 to 0.82 respectively) 
 
Multivariate analysis showed that diabetes increased the risk 
for lower primary patency (HR, 1.45; 95% CI, 1.06 to 1.99) and 
arterial diameter significantly influenced secondary patency 
(HR, 0.69; 95% CI, 0.56 to 0.84) 
 
Primary failure occurred in 26% of AVF 
 
21.2% of AVF incurred a complication, and 54% of interventions 
happened before it was viable for HD 
 
T. Wilmink, L. 
Hollingworth, 
S. Powers, C. 
Allen, I. 
Dasgupta 
(2016). 
Birmingham, 
UK.25 
Natural 
history of 
common 
autologous 
arteriovenous 
fistulae: 
consequences 
for planning 
of dialysis 
access 
To determine 
primary failure, 
maturation times, 
and survival of 
common AVFs in 
order to aid future 
AVF planning 
Retrospe
ctive 
longitudi
nal 
cohort 
study 
 
n = 
1,206 
fistula 
operati
ons 
 
The study 
population 
consisted of 
patients 
undergoing AVF 
creation at a 
single centre 
from December 
1, 2002-
December 31, 
2011. 
Primary failure occurred in 23% of AVFs in the study; 75% were 
needled for dialysis and 74% were functional 
  
RCAVFs had better survival than other AVFs, leading to more 
cumulative dialysis time 
 
Pre-dialysis AVF creation resulted in better AVF survival 
 
10 weeks of maturation should be allowed before commencing 
dialysis on an AVF for 50% survival, 16 weeks for 75% survival 
 
Irrespective of age, the best available option is RCAVF creation 
4 months before estimated dialysis commencement date 
 
Regarding the fistulas themselves, the results of this study are 
consistent with what was reported in a meta-analysis by Al-Jaishi et al., 
in 2014.24 They reported a primary patency of 60% at 1 year and 51% at 
2 years. Secondary patency was 71% and 64% at one and two years, 
respectively.24 The pooled primary failure from the same study was 
23%.24 The current study found primary patency to be 60-70% while 
primary failure ranged from 20-26%. Secondary patency was difficult to 
estimate due to variations in reporting between the different 
publications. However, the abandonment rate for the fistulas ranged 
from 37-51%, which leads to the conclusion that the secondary patency 
may be lower in this review.  
 
The success of AVFs can be predicted by multiple factors but the most 
accurate methods reviewed in this study are preoperative arterial flow 
rate and minimum vein diameter measurements.30,32 Both of these 
parameters had high predictive capability compared to factors such as 
sex, age, morbidity status, lifestyle factor and fistula site.30,32 Other than 
arterial flow rate and vein diameter, there was discordance between 
the publications as to whether other factors correlated with AVF 
outcomes or not.  
 
All publications included in this review were deemed valid using the 
EBL critical appraisal tool. Using this method, a threshold of  75% of 
the specified criteria was necessary for validity in each individual 
section and cumulatively, in the individual articles. The lowest overall 
score was 86%, which was calculated for 3 different studies.13,21,33 The 
main area of methodological concern arose from population validity. 
Three studies were found to have assessed a poorly representative 
population, as all of them attained a score of 66%. Problematic areas 
for the population validity were: a small sample size, lack of clearly 
defined exclusion and inclusion criteria, and no randomization of 
subjects in comparative studies. For the rest of the validity calculation, 
all studies were found to be diligently designed other than the 
pervasive theme of ambiguity regarding whether the investigators 
played a role in delivering a service to the target population or not. 
 
The articles included in this study were stringently examined using a 
standardized appraisal tool, reducing bias in calculating the validity of 
the selected publications. The limitations of this study are that there 
were only two databases used to identify publications to be included 
in the review. The database search was only carried out by one 
investigator which leaves the possibility for selection and reporting 
bias. This review is limited by an English availability filter used in the 
database search. The free-full text filter may have removed potentially 
relevant articles.  
 
Future studies should be directed to the application of preoperative 
vasculature assessment for prediction of AVF outcomes. Further 
investigation into the reasons for late referrals to nephrology and 
vascular surgery in ESRD patients would also be beneficial. Finally, 
examining the rate of eGFR decline in patients to try and make 
standardized recommendations for when to refer them for AVF 
consultation based on their diminishing renal function could provide 
important and topical data. 
 
Conclusions 
The gold standard for vascular access is still the AVF. With the aging 
global population, there will be an increasing demand for dialysis, 
which necessitates better standardization regarding patient referral for 
AVF creation. There are large variations in vascular access use between 
countries, despite HD patients faring much better when being dialyzed 
through an AVF as opposed to AVGs or CVCs. A concerted effort is 
required to try and meet the KDOQI guidelines for timely vascular access 
creation, improved AVF function and enhanced patient survival. 
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Appendix 
 
Appendix A. Full EBL Critical Appraisal Checklist for all articles included in review. 
 
Legend: Y, N, U, N/A 
Calculation for section validity: (Y+N+U=T): If Y/T <75% or if N+U/T > 25% then you can safely conclude that the section identifies significant omissions and that the 
study’s validity is questionable. It is important to look at the overall validity as well as section validity. 
 
Calculation for overall validity: (Y+N+U=T): If Y/T ≥75% or if N+U/T ≤ 25% then you can safely conclude that the study is valid. 
 
EBL Critical Appraisal Checklist27 Al-Jaishi 
et al 
(2015)29 
Biuckians 
et al 
(2008)26 
Dageforde 
et al 
(2015)30 
Ethier 
et al 
(2008)13 
Kimball 
et al 
(2011)1 
Korepta 
et al 
(2016)21 
Lee et 
al 
(2012)33 
Masengu 
et al 
(2016)32 
Schinstock 
et al 
(2001)31 
Wilmink 
et al 
(2016)25 
Se
ct
io
n 
A:
 P
op
ul
at
io
n 
Is the study population 
representative of all users, actual 
and eligible, who might be 
included in the study? 
Y Y N Y Y Y Y Y Y Y 
Are inclusion and exclusion 
criteria definitively outlined? 
Y Y Y N Y Y Y Y Y Y 
Is the sample size large enough 
for sufficiently precise estimates? 
Y N Y Y N N N N Y Y 
Is the response rate large enough 
for sufficiently precise estimates? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Is the choice of population bias-
free? 
Y Y Y Y Y Y Y Y Y Y 
If a comparative study: 
a) Were participants randomized 
into groups? 
b) Were the groups comparable at 
baseline? 
c) If groups were not comparable 
at baseline, was incomparability 
addressed by the authors in the 
analysis? 
N/A N/A N/A N 
Y 
N/A 
N/A N 
Y 
N/A 
N 
Y 
N/A 
N/A N/A N/A 
Was informed consent obtained? N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Section A validity: 100% 75% 75% 66% 75% 66% 66% 75% 100% 100% 
Se
ct
io
n 
B:
 D
at
a 
Co
lle
ct
io
n 
Are data collection methods 
clearly described? 
Y Y Y N Y Y Y Y Y Y 
If a face-to-face survey, were 
inter-observer and intra-observer 
bias reduced? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Is the data collection instrument 
validated? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
If based on regularly collected 
statistics, are the statistics free 
from subjectivity? 
Y Y Y Y Y Y Y Y Y Y 
Does the study measure the 
outcome at a time appropriate for 
capturing the intervention’s 
effect?  
Y Y Y Y Y Y Y Y Y Y 
Is the instrument included in the 
publication? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Are questions posed clearly 
enough to be able to elicit precise 
answers? 
Y Y Y Y Y Y Y Y Y Y 
Were those involved in data 
collection not involved in 
delivering a service to the target 
population?  
U U U Y U U U U U U 
Section B validity: 80% 80% 80% 80% 80% 80% 80% 80% 80% 80% 
Se
ct
io
n 
C:
 D
es
ig
n 
Is the study type / methodology 
utilized appropriate? 
Y Y Y Y Y Y Y Y Y Y 
Is there face validity? Y Y Y Y Y Y Y Y Y Y 
Is the research methodology 
clearly stated at a level of detail 
that would allow its replication? 
Y Y Y Y Y Y Y Y Y Y 
Was ethics approval obtained? Y Y Y Y Y Y Y Y Y Y 
Are the outcomes clearly stated 
and discussed in relation to the 
data collection? 
Y Y Y Y Y Y Y Y Y Y 
Section C validity: 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Se
ct
io
n 
D:
 R
es
ul
ts
 
Are all the results clearly outlined? Y Y Y Y Y Y Y Y Y Y 
Are confounding variables 
accounted for? 
Y Y Y Y Y Y Y Y Y Y 
Do the conclusions accurately 
reflect the analysis? 
Y Y Y Y Y Y Y Y Y Y 
Is subset analysis a minor, rather 
than a major, focus of the article? 
Y Y Y Y Y Y Y Y Y Y 
Are suggestions provided for 
further areas to research? 
Y Y Y Y Y Y Y Y Y Y 
Is there external validity?  Y Y Y Y Y Y Y Y Y Y 
Section D validity: 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Overall Validity Score: 95% 90% 90% 86% 90% 86% 86% 90% 95% 95% 
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